The Food and Drug Administration on Friday approved the first drug in a brand-new class of treatments for acute myeloid leukemia.
The drug, ivosidenib — developed by Cambridge-based Agios Pharmaceuticals — is a once-daily pill that might replace chemotherapy for some people with refractory or relapsing AML, a type of blood cancer that forms in the bone marrow.
About the Authors Reprints
